MetaCap

Retension Pharmaceuticals (RTSN) vs Upstream Bio (UPB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Retension Pharmaceuticals is the larger company by market cap ($87.6 million vs $87.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

RTSN-0.19%UPB-66.17%
+61%-6%-72%
Oct 9, 20261 yearNov 20, 2026
RTSN-0.19%UPB-66.17%
+50%-11%-72%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

RTSN versus UPB key metrics
MetricRTSNUPB
Share price$10.51$1.59
Market cap$87.57M$87.15M
1-day change-19.22%-20.50%
YTD return—-94.14%
1-year return—-93.78%
EPS (TTM)$-2.61$-3.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$2.85M
Revenue growth (YoY)—+20.42%
Net income (latest FY)—$-143.44M
Operating margin—-5618.82%
Net margin—-5026.03%
52-week high$18.64$33.68
52-week low$9.23$1.56
Distance from 52-week high-43.62%-95.28%
Analyst consensusstrong_buybuy
Avg. price target upside+391.63%+1245.91%
Average volume144.93K1.01M
Shares outstanding8.33M54.81M
Employees1275
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Retension Pharmaceuticals

RTSN stock →

Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

About Upstream Bio

UPB stock →

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees

RTSN vs UPB FAQ

Which is bigger, Retension Pharmaceuticals or Upstream Bio?

Retension Pharmaceuticals (RTSN) is larger, with a market capitalization of $87.57M compared with $87.15M for Upstream Bio (UPB).

Are Retension Pharmaceuticals and Upstream Bio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons